Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$35.00
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | PFE Avg Daily Volume: 29,757,000
Last Update: 03/30/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 12.36%
Open: $0.00
Previous Close: $35.00
52 Week Range: $27.51 - $35.45
Oustanding Shares: 6,128,855,392
Market Cap: 212,025,718,448
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 7 7
Moderate Buy 1 1 1 1
Hold 4 4 3 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.93 1.93 1.92 2.00
Latest Dividend: 0.28
Latest Dividend Yield: 3.24%
Dividend Ex-Date: 02/04/15
Price Earnings Ratio: 24.49
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
24.49 24.30 27.35
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.54% 9.79% 54.56%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.80 -0.26 -0.10
Net Income -58.50 0.04 0.01
EPS -55.50 0.13 0.04
Earnings for PFE:
EBITDA 19.04B
Revenue 49.61B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.50 $0.54 $2.08 $2.24
Number of Analysts 7 7 10 9
High Estimate $0.56 $0.55 $2.10 $2.35
Low Estimate $0.45 $0.53 $2.06 $2.13
Prior Year $0.57 $0.58 $2.26 $2.08
Growth Rate (Year over Year) -12.78% -7.14% -8.10% 7.79%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
You can't help but feel better about both groups.

Pfizer Getting Money Flow Real Money Pro($)

And the chart says it's in for a very solid 2015.
Bullish
Mar 23, 2015 | 7:48 AM EDT
Shares of PFE now seen reaching $45, according to Jefferies. Estimates also upped, as the Ibrance should drive growth and the company c...
Which dividend stocks gain or suffer from the next currency move?  
It is no pipedream that the stock could trade to $240.

Pfizer Pullback Begins Real Money Pro($)

A continued fade back down offers a buying opportunity.
Bullish
Feb 09, 2015 | 7:10 AM EST
PFE was upgraded from Market Perform, to Outperform, BMO Capital said. $36 price target. Hospira deal could mark an inflection point in...
The logic of owning the pure play is attractive.
Bullish
Feb 04, 2015 | 8:08 AM EST
PFE estimates were raised through 2016, BMO Capital said. Company received accelerated approval for breast cancer treatment. Market Per...
The financial version will affect global equity markets.

Columnist Conversations

Consistent with a theme of Jim "El Capitan" Cramer that Eurozone economies are improving and my short US bond ...
Much was talked about yesterday regarding the new blog post of former Fed Chair Ben Bernanke, currently of the...
Early yesterday I spoke here about the position we had on RH, and late in the day we sold this position and ro...
The only guarantee that investors will have in the second quarter is that quantitative easing by the European ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.